Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/Gastroenterology.2.031
Treatment and Drug Resistance to Helicobacter Pylori: A Brief Review
Vinícius Lima de Souza Gonçalves1, Jonathan Santos Apolonio2, Ronaldo Teixeira da Silva Junior2, Maria Luísa Cordeiro Santos2, Beatriz Rocha Cuzzuol2, Marcel Silva Luz2, Fabian Fellipe Bueno Lemos2, Hanna Santos Marques1, Camilo Santana Silva2, Mariana Miranda Sampaio2, Bruna Teixeira da Costa2, Fabrício Freire de Melo2,*
- 1Universidade Estadual do Sudoeste da Bahia, Vitória da Conquista 45083-900, Bahia, Brazil
- 2Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil
Fabrício Freire de Melo, email@example.com
Received Date: October 10, 2021
Accepted Date: November 02, 2021
de Souza Gonçalves VL, Apolonio JS, da Silva Júnior RT, Santos MLC, Cuzzuol BR, Luz MS, et al. Treatment and Drug Resistance to Helicobacter Pylori: A Brief Review. Arch Gastroenterol Res. 2021; 2(3): 75-78.
Copyright: © 2021 de Souza Gonçalves VL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Helicobacter pylori, Antimicrobial resistance, Treatment
Helicobacter pylori is a gram-negative, spiral-shaped bacterium that inhabits the gastric environment of 60.3% of the global population. Though most individuals infected with the bacterium remain asymptomatic, it is known that this infection plays a pivotal role in the development of diseases such as chronic gastritis, peptic ulcer, gastric cancer and gastric MALT lymphoma. Hence, eradication of H. pylori is associated with the potential prevention of many gastric and extra gastric diseases, such as gastric cancer.
HIV RNA Load and Antiretroviral Drug Resistance of HIV-1 Strains in Chad on Dried Blood Spots: A Pilot Study
In low-income Sub-Saharan Africa countries, peripheral blood HIV RNA levels monitoring twice a year in antiretroviral (ARV) drugs treated patient is a major WHO recommendation since 2013.
Zimbabwe is one of the countries in Southern Africa most affected by the Human Immunodeficiency Virus (HIV) epidemic. The country has the third highest HIV prevalence (12.5% among 15-49 years) in the region, with an estimated 1.4 million people living with HIV (PLHIV) to date.